Navigation Links
Study shows no increased risk of breast cancer for non-carriers in families with BRCA gene mutation
Date:10/31/2011

In this News Digest:

  • Summary of a study being published online Oct. 31, 2011, in the Journal of Clinical Oncology finding that close relatives of women who carry mutations in a BRCA gene - but who themselves do not have such genetic mutations -- do not have an increased risk of developing breast cancer compared to relatives of women with breast cancer who do not have such mutations. These results run counter to a previous study showing a higher risk for these women, and suggest they may not need extra cancer screening and other preventive measures.
  • Quote for attribution to Andrew Seidman, MD, American Society of Clinical Oncology Cancer Communications Committee member and breast cancer specialist.
  • Links to additional information on http://www.Cancer.Net, ASCO's patient Website

A population-based analysis of more than 3,000 families including women with breast cancer has found that close relatives of women who carry mutations in a BRCA gene - but who themselves do not have such genetic mutations - do not have an increased risk of developing breast cancer compared to relatives of women with breast cancer who do not have such mutations. While these results support most previous evidence regarding risks for non-carriers of BRCA mutations, they run counter to a 2007 study that indicated first-degree relatives (mothers, sisters and daughters) of women with BRCA gene mutations are several times more likely than the general population to develop breast cancer - despite not having the mutation themselves. The new findings suggest that women who test negative for the mutation may not need extra cancer screening and other increased preventive measures.

"This new study gives reassurance to non-carriers that they do not have an increased risk due to the familial mutation, and should be regarded the same as other non-carriers with first-degree relatives who have had breast cancer," said study first author Allison Kurian, MD, assistant professor of medicine and health research and policy at Stanford University School of Medicine. "One strength of the current study is the control women it used as a yardstick for comparing the breast cancer incidence in non-carriers of family-specific mutations. The control women were also relatives of breast cancer patients, but of patients without mutations. This is a more appropriate yardstick than average risk in the general population, since close relatives of all breast cancer patients have somewhat higher than average risks."

Women who inherit a mutation in the BRCA1 or BRCA2 gene carry a 5- to 20-fold higher risk of developing breast or ovarian cancers. First-degree relatives who have not inherited the same familial BRCA mutation have been considered to have a considerably lower risk for breast cancer.

In 2007, a study of women who tested negative for a specific familial BRCA mutation showed they had a 2- to 5-fold increased risk of developing breast cancer; which could be considered comparable to the risk of having a BRCA mutation. According to Kurian, the results raised concerns that non-carriers might require similar screening and preventive measures as their mutation-carrying relatives, such as annual breast MRI and prophylactic surgery, and cast some doubt on the meaning of a negative BRCA test.

Kurian said that the studies had looked at women who were in cancer family clinics and compared their breast cancer risk to that of women in the general population. Women from cancer family clinics were more likely to have intensive screening, and breast cancer risks tend to be higher among close relatives of breast cancer patients than those in the general population.

The investigators took a different approach in this research by studying women with breast cancer in 3,047 families in three population-based cancer registries in Northern California (1,214), Australia (799) and Canada (1,034) through a consortium called the Breast Cancer Family Registry. They found 292 families in which a woman had a BRCA mutation. This is the largest analysis to date of breast cancer risk of non-carriers of family-specific BRCA mutations.

They compared the risk of breast cancer among first-degree relatives of breast cancer patients who did and did not carry a BRCA mutation and found no significant difference. This means that non-carriers of a familial BRCA mutation did not have a markedly elevated risk of developing breast cancer.

The investigators also found that a small percentage of women - 3.4 percent of women in the general populations of Australia, Canada and the U.S. - who are at highest risk for unexplained reasons (reasons other than a BRCA mutation) account for approximately 32 percent of all breast cancer cases, reflecting the wide range of factors that could play a role in breast cancer development. Recent research suggests that many different genetic variants affect breast cancer risk, and that the women at highest risk have inherited many of these variants.

"Earlier reports of higher risk among non-carriers of family-specific BRCA mutations compared to risks in the general population may reflect a comparison of women with and without a family history of breast cancer," noted senior author Alice Whittemore, PhD, professor of epidemiology and biostatistics at Stanford University School of Medicine. "The control group we used - relatives of breast cancer patients in families without a BRCA mutation - was important. The results suggest that women who test negative for their family's BRCA mutation have no greater breast cancer risk than a woman who also has relatives with breast cancer but no family-specific mutation."


'/>"/>
Contact: Nicole Fernandes
nicole.fernandes@asco.org
571-483-1354
American Society of Clinical Oncology
Source:Eurekalert

Related medicine news :

1. The freshman 15 is just a myth, nationwide study reveals
2. First-of-its-kind study creates new tool for targeted cancer drug development
3. Study finds community counseling reduced the prevalence of TB on a budget
4. Practice Doesnt Always Make Perfect, Study Suggests
5. NYUCN receives $4.2 million NIH/NIDA grant to study injecting drug users in Kenya
6. NYUCN receives $2.8 million NIH/NIAID grant to study combination HIV prevention for Kenyan youth
7. Study finds no link between elderly patient activity and hospital falls
8. UT study looks at manual wheelchair use, exercise and calorie burning
9. Study finds specific gene linked to cold sore susceptibility
10. Poorer Countries Have Higher Rates of Stroke, Study Finds
11. NYUCN receives $299 thousand from NCSBN to study patient safety in nursing homes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... Ron Norman, CEO of Team ... week about the value of senior executives, pointed to a quote from William ... has brought us to the present and will lead us into the future," ...
(Date:9/20/2017)... ... 20, 2017 , ... “The Foggy Road to Moorwick”: the adventures of a young Scottish girl ... published author, Jeanine Liston, a busy mother of five who used her time waiting for ... this book for over twenty years. It was a way to give some meaning ...
(Date:9/20/2017)... ... September 20, 2017 , ... “They Sang At Her ... for a murderer starts revealing the skeletons in their closets. “They Sang At Her ... is now fifty-six years young and married with five children and twelve grandchildren. Before ...
(Date:9/19/2017)... ... September 19, 2017 , ... With a series of ... more than $15,000 in just a couple of weeks for those affected by ... world-class instructor seminars, organizers expect to double those initial funds with the “Submit ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola ... strategic marketing leader, Denise Flannery, to its strategic advisory and client development team. ... Denise will work with clients across different industries to develop and implement market-justified ...
Breaking Medicine News(10 mins):
(Date:9/1/2017)... 1, 2017 Michael Penna , President ... highlights opportunities for growth in his response to the ... Equity is seeking a buyer for eMDs. Penna,s company, ... healthcare solutions Value Added Reseller and national leader in ... "As the healthcare market continues to dictate ...
(Date:9/1/2017)...  Bayer will present the latest research from across its ... (ESMO) 2017 Congress, September 8-12 in Madrid, Spain ... clinical data on Bayer,s marketed portfolio and late-stage compounds as ... "We value the opportunity to ... at ESMO," said Carsten Brunn , Head of Pharmaceuticals, ...
(Date:8/29/2017)... Va. , Aug. 29, 2017 ivWatch, LLC, the ... peripheral IV infiltrations, announced it has been awarded an Innovative Technology ... company in the country. ... continuous monitoring device to aid in the early detection of peripheral ... The Innovative ...
Breaking Medicine Technology: